Reported Standalone quarterly numbers for Lincoln Pharmaceuticals are:Net Sales at Rs 112.46 crore in March 2023 up 9.67% from Rs. 102.54 crore in March 2022.
Quarterly Net Profit at Rs. 12.56 crore in March 2023 up 13.95% from Rs. 11.02 crore in March 2022.
EBITDA stands at Rs. 20.54 crore in March 2023 up 6.26% from Rs. 19.33 crore in March 2022.
Lincoln Pharma EPS has increased to Rs. 6.27 in March 2023 from Rs. 5.50 in March 2022.
Lincoln Pharma shares closed at 394.40 on May 25, 2023 (NSE) and has given 22.28% returns over the last 6 months and 49.28% over the last 12 months.
| Lincoln Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Mar'23 | Dec'22 | Mar'22 | | Net Sales/Income from operations | 112.46 | 133.77 | 102.54 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 112.46 | 133.77 | 102.54 | | EXPENDITURE | | Consumption of Raw Materials | 33.97 | 47.74 | 43.63 | | Purchase of Traded Goods | 10.04 | 20.60 | 8.38 | | Increase/Decrease in Stocks | 4.49 | -4.42 | -6.58 | | Power & Fuel | -- | -- | -- | | Employees Cost | 23.05 | 23.44 | 17.28 | | Depreciation | 2.41 | 2.26 | 2.00 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 24.31 | 19.66 | 22.39 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 14.18 | 24.49 | 15.44 | | Other Income | 3.95 | 6.36 | 1.89 | | P/L Before Int., Excpt. Items & Tax | 18.13 | 30.85 | 17.33 | | Interest | 1.15 | 0.33 | 0.57 | | P/L Before Exceptional Items & Tax | 16.98 | 30.52 | 16.76 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 16.98 | 30.52 | 16.76 | | Tax | 4.42 | 8.90 | 5.74 | | P/L After Tax from Ordinary Activities | 12.56 | 21.61 | 11.02 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 12.56 | 21.61 | 11.02 | | Equity Share Capital | 20.03 | 20.03 | 20.03 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 6.27 | 10.79 | 5.50 | | Diluted EPS | 6.27 | 10.79 | 5.50 | | EPS After Extra Ordinary | | Basic EPS | 6.27 | 10.79 | 5.50 | | Diluted EPS | 6.27 | 10.79 | 5.50 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
